Amyloid PETs are commonly negative in suspected Alzheimer's disease with an increase in CSF phosphorylated-tau protein concentration but an Aβ42 concentration in the very high range: a prospective study.
Fiche publication
Date publication
avril 2019
Journal
Journal of neurology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr KARCHER Gilles, Pr MARIE Pierre-Yves, Pr VERGER Antoine
Tous les auteurs :
Manca C, Rivasseau Jonveaux T, Roch V, Marie PY, Karcher G, Lamiral Z, Malaplate C, Verger A
Lien Pubmed
Résumé
Atypical cerebrospinal fluid (CSF) patterns, involving an increase in the concentration of phosphorylated-tau (P-tau) proteins but normal amyloid-β concentration, are not uncommon in patients with mild neurocognitive disorders and suspected Alzheimer's disease (AD). In these conditions, however, AD diagnosis may be ruled out in the absence of any amyloid deposition at positron-emission tomography (PET). This pilot cross-sectional study was aimed to determine whether this negativity of amyloid PET can be predicted by CSF profiles in such patients.
Mots clés
Alzheimer’s disease, Amyloid PET, Aß42, CSF biomarkers, Quantitative analysis
Référence
J. Neurol.. 2019 Apr 8;: